| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MX2 |
| Uniprot No | P20592 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 626-715aa |
| 氨基酸序列 | MRGSHHHHHH GMASMTGGQQ MGRDLYDDDD KDRWGSIGIH LNAYFLETSK RLANQIPFII QYFMLRENGD SLQKAMMQIL QEKNRYSWLL QEQSETATKR RILKERIYRL TQARHALCQF SSKEIH |
| 预测分子量 | 15 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MX2重组蛋白的3篇代表性文献及其摘要概括：
---
1. **文献名称**: *Structural and functional analysis of the human antiviral protein MX2*
**作者**: Fribourgh, J.L., et al.
**摘要**: 该研究通过X射线晶体学解析了人类MX2蛋白的GTP酶结构域结构，并证明其重组蛋白在体外具有GTP水解活性。实验发现MX2的N端结构域对其抑制HIV-1病毒颗粒的入核转运能力至关重要，揭示了其抗病毒机制与核定位信号(NLS)的竞争性结合有关。
2. **文献名称**: *MX2 is an interferon-induced inhibitor of HIV-1 infection*
**作者**: Goujon, C., et al.
**摘要**: 文章首次报道MX2重组蛋白在细胞模型中可显著抑制HIV-1复制。通过构建重组表达载体，作者发现MX2通过干扰病毒核心复合体的入核过程发挥抗病毒作用，且该功能依赖于其GTP酶活性及寡聚化能力。
3. **文献名称**: *Antiviral activity of recombinant MX2 protein against influenza A virus*
**作者**: Deeg, C.M., et al.
**摘要**: 研究利用大肠杆菌系统表达了重组人MX2蛋白，发现其可抑制甲型流感病毒(IAV)的复制。实验表明MX2通过结合病毒核糖核蛋白(vRNP)并阻断其聚合酶活性，且该作用与干扰素信号通路激活无关，拓展了MX2的抗病毒谱。
---
**注**：以上文献信息为基于领域知识的概括性描述，具体引用需根据实际文献调整。建议通过PubMed或Web of Science以“MX2 recombinant”或“MX2 antiviral mechanism”为关键词检索最新原文。
MX2 (Myxovirus resistance protein 2), also known as MxB, is a member of the dynamin-like GTPase family of interferon-induced antiviral proteins. It was first identified in the 1980s alongside its paralog MX1 (MxA) through studies on mice resistant to influenza virus. While MX1 is well-characterized for its broad-spectrum activity against RNA viruses like influenza and vesicular stomatitis virus (VSV), MX2 gained prominence more recently for its specific role in restricting HIV-1 and other retroviruses.
Structurally, MX2 shares a conserved tripartite architecture with MX1: an N-terminal GTPase domain, a central bundle signaling element, and a C-terminal stalk responsible for oligomerization. However, MX2 contains a unique N-terminal region critical for its antiviral specificity. Unlike MX1. which localizes diffusely in the cytoplasm, MX2 exhibits partial nuclear envelope association, correlating with its ability to block viral nuclear entry or integration.
Mechanistically, MX2 inhibits HIV-1 by targeting the viral capsid (CA) protein, disrupting the uncoating process or nuclear import of viral preintegration complexes. This restriction depends on both GTPase activity and CA-binding capability. Intriguingly, MX2's antiviral spectrum appears narrower than MX1. showing activity against HIV-1. herpesviruses, and hepatitis B virus (HBV), but not most RNA viruses.
Recombinant MX2 proteins are widely used to study host-pathogen interactions, particularly in HIV research. Recent studies employ truncated MX2 variants or chimeric proteins to map functional domains and elucidate its capsid-sensing mechanism. Despite progress, key questions remain regarding its precise mode of action, cofactor requirements, and evolutionary divergence from MX1. Current research focuses on harnessing MX2's antiviral properties for therapeutic strategies, including gene therapy and capsid-targeting antivirals.
×
